Open access

Implementing multimodal liquid biopsy in glioblastoma: A prospective feasibility study of a standardized clinical workflow.

M. Chiapponi Fabiola Cappella Laura Andreacchio Ruggero Antonini V. Liverotti Elisa Carelli Gaia Goteri J. Sabbatinelli Elisa Bartoli Alessandra Filosa A. Giuliani Matilde Sbriscia A. Procopio M. Dobran

Oct 2026 · Neuro-Oncology Practice · Vol 13 5, pp. 939-949 · 0 citations

Medicine

TL;DR

The feasibility of integrating multimodal liquid biopsy and volumetric imaging into routine neurosurgical practice for GBM is demonstrated, and the proposed workflow provides a reproducible foundation for larger studies aimed at advancing clinical implementation of liquid biopsy strategies.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Review Open access Aug 2026

Liquid Biopsy for Glioblastoma: Emerging Biomarkers, Clinical Utility, Current Challenges and Future Perspectives - A Narrative Review

Liquid biopsy represents a promising complementary approach to conventional tissue pathology and neuroimaging in glioblastoma and its greatest future value may lie in longitudinal molecular monitoring and integration with MRI, radiomics, artificial intelligence, and other molecular profiling approaches.

Usha Topalkatti, Jhansi Mani Mahadeva · International Journal of Inn... · 0 citations

Review Open access Sep 2026

Circulating Tumor DNA as a Liquid Biopsy for Glioma Detection in Cerebrospinal Fluid and Plasma: A Systematic Review and Meta-Analysis

The utility of ctDNA, particularly CSF ctDNA, as a complementary diagnostic tool in neuro-oncology is supported, with a promising performance of ctDNA analysis in patients with diffuse gliomas as a liquid biopsy strategy.

Christian Amezquita-Contreras, Angel Bueno, Diego Z. Arellano et al. · Neuro-Oncology Advances · 0 citations

Open access Oct 2026

Liquid biopsy using circulating miRNAs for the identification of recurrence-associated biomarkers in glioblastoma CNS WHO grade 4

Glioblastoma CNS WHO Grade 4 (GBM) is associated with poor prognosis and high recurrence rates despite the current therapeutic approaches. Conventional imaging, in particular Magnetic Resonance Imaging (MRI), is primarily used during follow-up to detect tumor recurrence but has limited ability to distinguish recurr...

R. Muhtadi, Christian D. Diehl, N. Schmid et al. · Frontiers in Oncology · 0 citations

Review Sep 2026

Liquid biopsy in glioblastoma: emerging technologies and translational opportunities.

A multimodal decision matrix and an artificial intelligence (AI)-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics are introduced to enhance minimal residual disease detection and guide precision neuro-oncology.

Olawumi Giwa, Yonit Leykind, I. Altman et al. · Trends in Biotechnology · 0 citations

Case report Open access Sep 2026

Case Report: Concordance of cerebrospinal fluid-derived circulating tumor DNA with tumor tissue in spinal glioblastoma associated with Lynch syndrome

Background Spinal glioblastoma (GBM) is an exceptionally rare entity and poses significant diagnostic challenges due to a substantial risk of neurological morbidity with surgical biopsy. Tissue-based analyses are frequently limited by sampling constraints and tumor heterogeneity. Conventional diagnostic modalities, inc...

Carlen A. Yuen, David O. Kamson, Chang-Rui Xiao et al. · Frontiers in Oncology · 0 citations

Review Open access Aug 2026

Integrating Radiogenomics and CSF-Based Liquid Biopsy Sequencing for Precision Neuro-Oncology

Glioblastoma and diffuse gliomas pose major therapeutic challenges due to marked intratumoral heterogeneity, limited tissue accessibility, and the blood–brain barrier. Tissue-based next-generation sequencing (NGS) remains essential for WHO CNS5 molecular classification, yet it is invasive and poorly suited to serial mo...

K. Kubiak, Edyta Szurowska · International Journal of Mol... · 0 citations